More Avecho Biotechnology Limited news
Avecho Biotechnology LimitedASX: AVE

Prospectus

Apr 3, 2023 at 12:02 AM EDT · Issued by Avecho Biotechnology Limited

Filed with ASX · Apr 3, 2023 at 12:02 AM EDT

On 6ix: 6ix.com/news/prospectus-90

Avecho Biotechnology Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Avecho Biotechnology Limited on 6ix

In the deck

  • Avecho Biotechnology — Investor Presentation (April 2023)32 slidesApr 3, 2023

Story so far

  • AVE receives firm commitment to raise $5.06 via placementFeb 10, 2021

Earlier from Avecho Biotechnology

  • Entitlement Offer to raise $11m for Phase 3 clinical trialApr 3, 2023
  • Clinical CBD program expands with the Lambert InitiativeFeb 21, 2023
  • December 2022 Quarterly Activities Report & Appendix 4CJan 30, 2023
  • Athenex submits Avechos phytonadione to FDA pre-INDJan 12, 2023
  • Avecho receives ethics approval for Phase III CBD trialDec 21, 2022

Later from Avecho Biotechnology

  • Investor PresentationApr 3, 2023
  • March 2023 Quarterly Activities Report & Appendix 4CApr 27, 2023
  • Results of Entitlement OfferMay 8, 2023
  • AVE commences manufacturing for Phase III trialMay 16, 2023
  • Avecho licenses TPM for use in cancer drugsMay 22, 2023
All Avecho Biotechnology news releases↗

Follow Avecho Biotechnology into a list and get an email when it puts out news.

Follow Avecho Biotechnology
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer